Ethics of randomised controlled trials--not yet time to give up on equipoise.
In this commentary on Fries and Krishnan's argument that 'design bias' undermines the status of equipoise as the ethical justification for randomised controlled trials, it is argued that their argument is analogous to Bayesian arguments for the use of informative priors in trial design, but that this does not undermine the importance of equipoise. In particular, mismatches between the outcomes of interest to industrial sponsors of research and outcomes of interest to patients and clinicians ensure that in many cases industry-sponsored trials can fail to reflect the reasonable equipoise of working clinicians.
Ashcroft
Richard E
RE
Medical Ethics Unit, Imperial College London, London, UK. r.ashcroft@imperial.ac.uk
D001499:Bayes Theorem; D015982:Bias; D015415:Biomarkers; D017326:Clinical Trials, Phase III as Topic / Q000941:ethics / Q000706:statistics & numerical data; D003469:Culture; D006801:Humans; D028681:Moral Obligations; D016032:Randomized Controlled Trials as Topic / Q000941:ethics* / Q000706:statistics & numerical data; D012107:Research Design; D016896:Treatment Outcome
D015415:Biomarkers